 FOSTER CITY, Calif., July 17, 2019 PRNewswire -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of 15.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be 75,000,000. The shares are expected to begin trading on the Nasdaq Global Market on July 18, 2019 under the symbol MIRM. 